

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34⁺ hematopoietic progenitor cells in patients with sickle cell disease: interim results

Farid Boulad,^{1,2} Tsiporah Shore,³ Koen van Besien,³ Caterina Minniti,⁴ Mihaela Barbu-Stevanovic,⁵ Sylvie Wiener Fedus,⁶ Fabiana Perna,² June Greenberg,⁷ Danielle Guarneri,⁷ Vijay Nandi,⁵ Audrey Mauguen,⁸ Karina Yazdanbakhsh,⁵ Michel Sadelain² and Patricia A. Shi^{4,5}

¹Department of Pediatrics, BMT Service, Memorial Sloan Kettering Cancer Center, New York; ²Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York; ³Bone Marrow and Hematopoietic Stem Cell Transplant Program, Weill Cornell Medicine/ New York Presbyterian Hospital, New York; ⁴Sickle Cell Program, Division of Hematology, Albert Einstein College of Medicine, Bronx; ⁵Lindsley F. Kimball Research Institute, New York Blood Center, NY; ⁶Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York; ⁷Division of Hematology and Oncology, Weill Cornell Medicine /New York Presbyterian Hospital, NY and ⁸Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

doi:10.3324/haematol.2018.199414

©2018 Ferrata Storti Foundation

An incorrect version of sentence appeared on May 2018 Issue, pages 773.

Our target goal of mobilizing at least 30 CD34⁺ cells/ μ L was, however, reached in only 50% of patients given the plerixafor dose of 80 μ g/kg, 33% of patients given 160 μ g/kg, and 33% of patients given 240 μ g/kg.

The corrected version of sentence is published below.

Our target goal of mobilizing at least 30 CD34⁺ cells/ μ L was, however, reached in only 50% of patients given the plerixafor dose of 80 μ g/kg, 67% of patients given 160 μ g/kg, and 67% of patients given 240 μ g/kg.

An incorrect version of sentence appeared on May 2018 Issue, pages 777.

Eight of 15 patients (53%) with SCD treated with plerixafor reached the peripheral blood CD34 cell target count of at least 30 CD34⁺ cells/ μ L, including three of six patients treated at a dose of 240 μ g/kg.

The corrected version of sentence is published below.

Nine of 15 patients (60%) with SCD treated with plerixafor reached the peripheral blood CD34 cell target count of at least 30 CD34⁺ cells/ μ L, including four of six patients treated at a dose of 240 μ g/kg.